SCHEMBL21176189

SCHEMBL21176189

CC(NS(=O)(=O)CCc1ccccc1)C(=O)C(=O)NCC1CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.41
ALDH1A1 P00352 1/20 0.40
IDO1 P14902 1/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
MMP1 P03956 1/20 0.40
MMP7 P09237 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
PLG P00747 1/20 0.40
PLAU P00749 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
ACHE P22303 2/20 0.39
LMNA P02545 1/20 0.38
NAPEPLD Q6IQ20 2/20 0.38
FKBP1A P62942 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974906 0.88 F2 (0.43) MEN1KMT2AALDH1A1ITGB3ITGA2B
SCHEMBL19975409 0.81 GBA1 (0.51) MEN1POLBKMT2AALDH1A1
SCHEMBL19975118 0.81 ITGB3 (0.41) MEN1POLBKMT2AMAPTALDH1A1
SCHEMBL4619221 0.77 MMP8 (0.51) MEN1KMT2AALDH1A1IDO1MMP1
SCHEMBL4621065 0.77 MMP8 (0.51) MEN1KMT2AALDH1A1IDO1MMP1
SCHEMBL4621599 0.77 MMP8 (0.51) MEN1KMT2AALDH1A1IDO1MMP1
SCHEMBL19974910 0.76 POLB (0.47) MEN1POLBKMT2AALDH1A1SIGMAR1
SCHEMBL21176241 0.75 KMT2A (0.46) MEN1POLBKMT2AALDH1A1
SCHEMBL19975391 0.75 ITGAV (0.45) POLBKMT2AMAPTALDH1A1LMNA
SCHEMBL19975110 0.74 KMT2A (0.46) MEN1POLBKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885POLB 833/4885KMT2A 4031/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MEN1 4361/4885POLB 617/4885KMT2A 4177/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885POLB 833/4885KMT2A 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.